Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

Overall, 55.8% of infants were protected by either maternal RSV vaccination, nirsevimab, or both; 14.2% of infants were ...

As we enter cold and flu season, the medical community wants pregnant women to know it's now recommended they receive the RSV ...

Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

If you, for some reason, don’t get the RSV vaccine while you’re pregnant, you can (and should!) still protect your baby after ...

The effectiveness of the long-acting monoclonal antibody nirsevimab (Beyfortus) against primary care visits for lower ...

HealthDay News — In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according to research published in ...

One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infantsParis, October 9, ...

In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according to research published in the Sep. 26 ...